# Belite Bio, Inc: overview BLTE · Nasdaq · CIK 1889109 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/blte.md) · [Financials](/companies/blte/financials.md) · [Filings](/companies/blte/filings.md) · [Insiders](/companies/blte/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.01)](/filings/0001104659-24-033149.md) | [(0.63)](/filings/0001410578-25-000356.md) | [(1.19)](/filings/0001104659-26-037374.md) | [(1.18)](/filings/0001104659-26-037374.md) | [(2.31)](/filings/0001104659-26-037374.md) | | Free cash flow | $m | [(7.5)](/filings/0001104659-24-033149.md) | [(11.9)](/filings/0001410578-25-000356.md) | [(29.9)](/filings/0001104659-26-037374.md) | [(29.4)](/filings/0001104659-26-037374.md) | [(37.1)](/filings/0001104659-26-037374.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/blte/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Darwin Global Management, Ltd.](/funds/1839209.md) | 2026-06-30 | $456.6m | 3,077,219 | | Added +19,807 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $189.8m | 1,232,877 | | Added +118,093 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $110.2m | 715,332 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $76.2m | 494,564 | | Reduced −75,524 | | [MAVERICK CAPITAL LTD](/funds/934639.md) | 2026-06-30 | $61.0m | 396,311 | | New +396,311 | | [EVENTIDE ASSET MANAGEMENT, LLC](/funds/1442891.md) | 2026-06-30 | $60.2m | 390,829 | | Added +33,179 | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $55.0m | 357,199 | | Added +53,186 | | [Holocene Advisors, LP](/funds/1700574.md) | 2026-06-30 | $38.7m | 251,035 | | Reduced −243,460 | | [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $38.5m | 250,000 | | New +250,000 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $36.2m | 235,071 | | Added +33,662 | ## Recent filings [All 211 filings](/companies/blte/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 10:01 ET | [6-K](/filings/0001104659-26-116685.md) | Report of a foreign private issuer, period 2026-10-19 | 0001104659-26-116685 | | 2026-09-08 | 10:06 ET | [6-K](/filings/0001104659-26-105608.md) | Report of a foreign private issuer, period 2026-09-08 | 0001104659-26-105608 | | 2026-08-13 | 01:50 ET | [6-K](/filings/0001104659-26-095218.md) | Report of a foreign private issuer, period 2026-08-12 | 0001104659-26-095218 | | 2026-08-11 | 20:05 ET | [6-K](/filings/0001104659-26-094040.md) | Report of a foreign private issuer, period 2026-08-11 | 0001104659-26-094040 | | 2026-06-15 | 01:42 ET | [6-K](/filings/0001104659-26-073668.md) | Report of a foreign private issuer, period 2026-06-12 | 0001104659-26-073668 | | 2026-05-20 | 10:02 ET | [6-K](/filings/0001104659-26-064049.md) | Report of a foreign private issuer, period 2026-05-20 | 0001104659-26-064049 | | 2026-04-21 | 20:00 ET | [6-K](/filings/0001104659-26-045989.md) | Report of a foreign private issuer, period 2026-04-21 | 0001104659-26-045989 | | 2026-03-31 | 12:01 ET | [6-K](/filings/0001104659-26-037376.md) | Report of a foreign private issuer, period 2026-03-31 | 0001104659-26-037376 | | 2026-03-31 | 12:00 ET | [20-F](/filings/0001104659-26-037374.md) | Annual report of a foreign private issuer, period 2025-12-31 | 0001104659-26-037374 | | 2026-03-02 | 11:01 ET | [6-K](/filings/0001104659-26-021805.md) | Report of a foreign private issuer, period 2026-03-02 | 0001104659-26-021805 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-037374.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1889109 - Tickers: BLTE - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: E9 - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.